Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 3/20 | 0.44 |
| ▸ | BRAF | P15056 | 3/20 | 0.44 |
| ▸ | SRC | P12931 | 4/20 | 0.41 |
| ▸ | ABL1 | P00519 | 4/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | KDR | P35968 | 6/20 | 0.39 |
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.38 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.38 |
| ▸ | TEK | Q02763 | 1/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.38 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5416351 | 0.90 | RAF1 (0.45) | RAF1BRAFSRCABL1KDR | |
| SCHEMBL5418586 | 0.89 | RAF1 (0.51) | RAF1BRAFSRCABL1EGFR | |
| SCHEMBL544981 | 0.86 | KDR (0.43) | RAF1BRAFSRCABL1EGFR | |
| SCHEMBL545259 | 0.85 | BRAF (0.46) | RAF1BRAFKDR | |
| SCHEMBL5425682 | 0.83 | KDR (0.42) | RAF1BRAFSRCABL1EGFR | |
| SCHEMBL5423039 | 0.82 | BRAF (0.60) | RAF1BRAFSRCABL1EGFR | |
| SCHEMBL545439 | 0.82 | MAPK14 (0.44) | RAF1BRAFSRCABL1EGFR | |
| SCHEMBL546229 | 0.80 | MAPK14 (0.50) | RAF1BRAFSRCABL1EGFR | |
| SCHEMBL5430237 | 0.79 | BRAF (0.49) | RAF1BRAFSRCKDRFLT1 | |
| SCHEMBL545423 | 0.79 | MAPK14 (0.49) | RAF1BRAFSRCABL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149533-A1 | Bicyclic compounds with kinase inhibitory activity | MAP3K20, MAP3K1, MAP3K5 | RAF1 198/4885BRAF 215/4885SRC 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.